<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOLEUCOVORIN- levoleucovorin calcium pentahydrateÂ injection, solutionÂ </strong><br>Sandoz Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use levoleucovorin injection safely and effectively.  See full prescribing information for levoleucovorin injection.<br><br>LEVOLEUCOVORIN injection, solution for intravenous use<br><br>Initial U.S. Approval: 2008  (levoleucovorin)</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage (1)                                                                04/2011 </p>
<p class="Highlighta">Dosage and Administration, Reconstitution and Infusion Instructions (2.6)                                     04/2011 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Levoleucovorin injection is a folate indicated for:  (<a href="#section-1">1</a>)</p>
<dl>
<dt>â€¢</dt>
<dd>Rescue after high-dose methotrexate therapy in <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>.</dd>
<dt>â€¢</dt>
<dd>Diminishing the toxicity and counteracting the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.</dd>
</dl>
<p class="Highlighta"><span class="Bold">Limitations of Use</span>  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Levoleucovorin injection is not approved for <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> and <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemias</span>. Improper use may cause a hematologic remission while neurologic manifestations continue to progress. (1.1)  (<a href="#section-1">1</a>)</p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Do not administer intrathecally. (2.1)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">Levoleucovorin injection is dosed at one-half the usual dose of racemic d,l-leucovorin (2.1)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta"><span class="Bold">Levoleucovorin</span><span class="Bold"> injection Rescue </span><span class="Bold">After</span><span class="Bold"> High-Dose Methotrexate Therapy</span>  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">Levoleucovorin injection rescue recommendations are based on a methotrexate dose of 12 grams/m<span class="Sup">2</span> administered by intravenous infusion over 4 hours. Â Levoleucovorin injection rescue at a dose of 7.5 mg (approximately 5 mg/m<span class="Sup">2</span>) every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion. Determine serum creatinine and methotrexate levels at least once daily. Continue levoleucovorin injection administration, hydration, and urinary alkalinization (pH of 7.0 or greater) until the methotrexate level is below 5 x 10<span class="Sup">-8</span> M (0.05 micromolar). The levoleucovorin injection dose may need to be adjusted. (2.3)  (<a href="#section-2">2</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Levoleucovorin Injection: 17.5 mL of a sterile solution containing levoleucovorin pentahydrate equivalent to 175 mg levoleucovorin and 0.83% sodium chloride. (3, 11, 16)  (<a href="#section-3">3</a>)</p>
<p class="Highlighta">Levoleucovorin Injection: 25 mL of a sterile solution containing levoleucovorin calcium pentahydrate equivalent to 250 mg levoleucovorin and 0.83% sodium chloride. (3, 11, 16)  (<a href="#section-3">3</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Levoleucovorin is contraindicated for patients who have had previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> attributed to folic acid or folinic acid. (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">Due to Ca<span class="Sup">++ </span>content, no more than 16 mL (160 mg) of levoleucovorin solution should be injected intravenously per minute. (5.1)  (<a href="#section-5">5</a>)</p>
<p class="Highlighta">Concomitant use of <span class="Italics">d</span><span class="Italics">,l</span><span class="Italics">-</span>leucovorin with trimethoprim-sulfamethoxazole for <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis carinii pneumonia</span> in HIV patients was associated with increased rates of treatment failure in a placebo-controlled study. (5.3)  (<a href="#section-5">5</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> were reported in patients receiving levoleucovorin. (6.3)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (38%), <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> (38%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (19%) were reported in patients receiving levoleucovorin as rescue after high dose methotrexate therapy. (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Levoleucovorin may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in susceptible patients. (7)  (<a href="#section-7">7</a>)</p></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Administration Guidelines</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Co-administration of Levoleucovorin Injection with Other Agents</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Levoleucovorin Injection After High-Dose Methotrexate Therapy</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosing Recommendations for Inadvertent Methotrexate Overdosage</a></h2>
<h2><a href="#section-2.5" class="toc">2.6 Reconstitution and Infusion Instructions</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Rate of Administration</a></h2>
<h2><a href="#section-5.2" class="toc">5.3 Potential for Interaction with Trimethoprim-Sulfamethoxazole</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies in High-Dose Methotrexate Therapy</a></h2>
<h2><a href="#section-6.2" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 High Dose Methotrexate Therapy</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_bf32b5a0-6987-4f88-8fd4-c626bd900eaf"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<dl>
<dt>â€¢</dt>
<dd>Levoleucovorin injection is a folate analog.</dd>
<dt>â€¢</dt>
<dd>Levoleucovorin injection rescue is indicated after high-dose methotrexate therapy in <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span>.</dd>
<dt>â€¢</dt>
<dd>Levoleucovorin injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_145c3c5f-d72f-4313-b769-d2441332ffa9"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Limitations of Use</h2>
<dl>
<dt>â€¢</dt>
<dd>Levoleucovorin injection is not approved for <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">pernicious anemia</span> and <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemias</span> secondary to the lack of vitamin B<span class="Sub">12</span>. Improper use may cause a hematologic remission while neurologic manifestations continue to progress.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_87d11d31-5689-4005-986b-e47da5abbf80"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e00b5b3e-b54a-4e7b-a9cc-4afd9cd15384"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Administration Guidelines</h2>
<p class="First">Levoleucovorin injection is dosed at <span class="Bold">one-half</span> the usual dose of racemic <span class="Italics">d</span><span class="Italics">,l</span>-leucovorin.</p>
<p><span class="Underline">Levoleucovorin</span><span class="Underline"> injection is indicated for intravenous administration only. </span><span class="Bold">Do not administer </span><span class="Bold">intrathecally</span><span class="Bold">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0e3141b-b575-4e0f-9de1-198f14e66969"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Co-administration of Levoleucovorin Injection with Other Agents</h2>
<p class="First">Due to the risk of precipitation, do not co-administer levoleucovorin injection with other agents in the same admixture.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3af8cb19-f550-4adb-abdb-c01e0159d389"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Levoleucovorin Injection After High-Dose Methotrexate Therapy</h2>
<p class="First">The recommendations for levoleucovorin injection rescue are based on a methotrexate dose of 12 grams/m<span class="Sup">2</span> administered by intravenous infusion over 4 hours (see methotrexate package insert for full prescribing information). Â  Levoleucovorin injection rescue at a dose of 7.5 mg (approximately 5 mg/m<span class="Sup">2</span>) every 6 hours for 10 doses starts 24 hours after the beginning of the methotrexate infusion.</p>
<p>Serum creatinine and methotrexate levels should be determined at least once daily. Levoleucovorin injection administration, hydration, and urinary alkalinization (pH of 7.0 or greater) should be continued until the methotrexate level is below 5 x 10<span class="Sup">-8</span> M (0.05 micromolar). The levoleucovorin injection dose should be adjusted or rescue extended based on the following guidelines.</p>
<p><span class="Bold">Table 1 </span><span class="Bold">Guidelines</span><span class="Bold"> for </span><span class="Bold">Levoleucovorin</span><span class="Bold"> Injection Dosage and Administration </span></p>
<table>
<col width="21%">
<col width="45%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Clinical Situation</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Laboratory Findings</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Levoleucovorin</span><span class="Bold"> Injection Dosage and Duration</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Normal Methotrexate Elimination</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Serum methotrexate level approximately 10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and less than 0.2 micromolar at 72 hours</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">7.5 mg IV q 6 hours for 60 hours (10 doses starting at 24 hours after start of methotrexate infusion).</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Delayed Late Methotrexate Elimination</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Serum methotrexate level remaining above 0.2 micromolar at 72 hours, and more than 0.05 micromolar at 96 hours after administration. </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Continue 7.5 mg IV q 6 hours, until methotrexate level is less than 0.05 micromolar.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Delayed Early Methotrexate Elimination and/or Evidence of Acute <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">Renal Injury</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Serum methotrexate level of 50 micromolar or more at 24 hours, or 5 micromolar or more at 48 hours after administration, OR; a 100% or greater increase in serum creatinine level at 24 hours after methotrexate administration (e.g., an increase from 0.5 mg/dL to a level of 1 mg/dL or more).</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">75 mg IV q 3 hours until methotrexate level is less than 1 micromolar; then 7.5 mg IV q 3 hours until methotrexate level is less than 0.05 micromolar. </p></td>
</tr>
</tbody>
</table>
<p>Patients who experience delayed early methotrexate elimination are likely to develop reversible <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. In addition to appropriate levoleucovorin injection therapy, these patients require continuing hydration and urinary alkalinization, and close monitoring of fluid and electrolyte status, until the serum methotrexate level has fallen to below 0.05 micromolar and the <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has resolved.</p>
<p>Some patients will have abnormalities in methotrexate elimination or renal function following methotrexate administration, which are significant but less severe than the abnormalities described in the table above. These abnormalities may or may not be associated with significant clinical toxicity. If significant clinical toxicity is observed, levoleucovorin injectionÂ  rescue should be extended for an additional 24 hours (total of 14 doses over 84 hours) in subsequent courses of therapy. The possibility that the patient is taking other medications which interact with methotrexate (e.g., medications which may interfere with methotrexate elimination or binding to serum albumin) should always be reconsidered when laboratory abnormalities or clinical toxicities are observed.</p>
<p>Delayed methotrexate excretion may be caused by accumulation in a third space fluid collection (i.e., <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>), <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or inadequate hydration. Under such circumstances, higher doses of levoleucovorin injection or prolonged administration may be indicated. </p>
<p>Although levoleucovorin injection may ameliorate the hematologic toxicity associated with high-dose methotrexate, levoleucovorin injection has no effect on other established toxicities of methotrexate such as the <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> resulting from drug and/or metabolite precipitation in the kidney.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1946e7ed-9aac-407a-b34e-567f3c8d28c0"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dosing Recommendations for Inadvertent Methotrexate Overdosage</h2>
<p class="First">Levoleucovorin injection rescue should begin as soon as possible after an inadvertent overdosage and within 24 hours of methotrexate administration when there is delayed excretion. As the time interval between antifolate administration [e.g., methotrexate] and levoleucovorin injection rescue increases, levoleucovorin injection effectiveness in counteracting toxicity may decrease. Levoleucovorin injection 7.5 mg (approximately 5 mg/m<span class="Sup">2</span>) should be administered IV every 6 hours until the serum methotrexate level is less than 10<span class="Sup">-8</span>  M. </p>
<p>Serum creatinine and methotrexate levels should be determined at 24 hour intervals. If the 24 hour serum creatinine has increased 50% over baseline or if the 24 hour methotrexate level is greater than 5 x 10<span class="Sup">-6</span> M or the 48 hour level is greater than 9 x 10<span class="Sup">-</span><span class="Sup">7</span>  M, the dose of levoleucovorin injection should be increased to 50 mg/m<span class="Sup">2</span> IV every 3 hours until the methotrexate level is less than 10<span class="Sup">-8</span> M. Hydration (3 L/day) and urinary alkalinization with NaHCO<span class="Sub">3</span>  should be employed concomitantly. The <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> dose should be adjusted to maintain the urine pH at 7.0 or greater.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_05b5cd4f-cb3b-4d8d-987d-c8f63d1d796f"></a><a name="section-2.5"></a><p></p>
<h2>2.6 Reconstitution and Infusion Instructions</h2>
<dl>
<dt>â€¢</dt>
<dd>Levoleucovorin contains no preservative. Observe strict aseptic technique during reconstitution of the drug product.</dd>
<dt>â€¢</dt>
<dd>Levoleucovorin solutions may be further diluted to concentrations of 0.5 mg/mL in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. The diluted solution using 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP may be held at room temperature for not more than 4 hours.</dd>
<dt>â€¢</dt>
<dd>Visually inspect the diluted solution for particulate matter and discoloration, prior to administration. CAUTION: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if cloudiness or precipitate is observed.</dd>
<dt>â€¢</dt>
<dd>No more than 16 mL of levoleucovorin injection (160 mg of levoleucovorin) should be injected intravenously per minute, because of the calcium content of the levoleucovorin solution.</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_a5106267-8a73-4d62-8c26-2948699ce2c6"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Levoleucovorin injection, 175 mg is supplied in a single-use vial containing 17.5 mL sterile solution. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.</p>
<p>Levoleucovorin injection, 250 mg is supplied in a single-use vial containing 25 mL sterile solution. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_6d7cc4f5-ab00-4cc3-9698-e3aabdfa3bef"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Levoleucovorin is contraindicated for patients who have had previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> attributed to folic acid or folinic acid.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_1b912f02-329d-44de-902b-68cb6bdf19ef"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0db17ed9-b8a9-4423-a20a-97a644bb084e"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Rate of Administration</h2>
<p class="First">Because of the Ca<span class="Sup">++ </span>content of the levoleucovorin solution, no more than 16 mL (160 mg of levoleucovorin ) should be injected intravenously per minute.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e408ba3-70a1-45a4-9a93-6f4dcc519ae2"></a><a name="section-5.2"></a><p></p>
<h2>5.3 Potential for Interaction with Trimethoprim-Sulfamethoxazole</h2>
<p class="First">The concomitant use of <span class="Italics">d</span><span class="Italics">,l</span><span class="Italics">-</span>leucovorin with trimethoprim-sulfamethoxazole for the acute treatment of <span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis carinii pneumonia</span> in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> was associated with increased rates of treatment failure and morbidity in a placebo-controlled study.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7d4eb15b-865b-4cd8-a294-a49468b2dee8"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b0ea6369-6e38-4325-8328-082c1901bc83"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies in High-Dose Methotrexate Therapy</h2>
<p class="First">Since clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The following table presents the frequency of adverse reactions which occurred during the administration of 58 courses of high-dose methotrexate 12 grams/m<span class="Sup">2</span> followed by levoleucovorin rescue for <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span> in 16 patients age 6 to 21. Most patients received levoleucovorin injection 7.5 mg every 6 hours for 60 hours or longer beginning 24 hours after completion of methotrexate. </p>
<p><span class="Bold">Table 2 Adverse Reactions with High-Dose Methotrexate Therapy</span></p>
<table>
<col width="27%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="13%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top"><p class="First"><span class="Bold">Body System/Adverse Reactions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (%) of Patients with Adverse Reactions</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Number (%) of Courses with Adverse Reactions</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">(N =16)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">(N = 58)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">All</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3+</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">All</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Grade 3+</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Gastrointestinal</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (37.5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">10 (17.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (37.5)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">14 (24.1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (18.8)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (5.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4189378" conceptname="Typhlitis">Typhlitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Respiratory</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Skin and Appendages</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Other</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal function abnormal</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">3 (5.2)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (6.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">1 (1.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Total number of patients</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">9 (56.3)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">2 (12.5)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Total number of courses</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">25 (43.1)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First">2 (3.4)</p></td>
</tr>
</tbody>
</table>
<p>The incidence of adverse reactions may be underestimated because not all patients were fully evaluable for toxicity for all cycles in the clinical trials. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> were observed, but could not be attributed to high-dose methotrexate with levoleucovorin rescue because patients were receiving other myelosuppressive chemotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a20c5cc-bc94-4daf-91a4-c122ca07ce42"></a><a name="section-6.2"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">Since adverse reactions from spontaneous reports are provided voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Spontaneously reported adverse reactions collected by the WHO Collaborating Center for International Drug Monitoring in Uppsala Sweden have yielded seven cases where levoleucovorin was administered with a regimen of methotrexate. The events were <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, temperature change and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>. For 217 adverse reactions (108 reports) where levoleucovorin was a suspected or interacting medication, there were 40 occurrences of â€œpossible allergic reactionsâ€?.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_693ab065-50fa-4390-ba47-b73dce8fb765"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone, and increase the frequency of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in susceptible children. It is not known whether folinic acid has the same effects. However, both folic and folinic acids share some common metabolic pathways. Caution should be taken when taking folinic acid in combination with anticonvulsant drugs.</p>
<p>Preliminary human studies<span class="Bold">Â  </span>have shown that small quantities of systemically administered leucovorin enter the CSF, primarily as its major metabolite, 5-methyltetrahydrofolate (5-MTHFA). In humans, the CSF levels of 5-MTHFA remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_bd3ca619-757b-459d-9412-f5e9758db444"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_26cf4ae1-98c5-4467-bf2d-6a93f6cdfaf1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold"><span class="Italics">Pregnancy Category C.</span></span> Animal reproduction studies have not been conducted with levoleucovorin. It is not known whether levoleucovorin can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity. Levoleucovorin should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_3d72a28c-ecf1-44c9-9fa4-9c92d1497bcc"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from levoleucovorin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_1fa464af-1cd0-456e-88b7-7b7b1e22bb51"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">[See <span class="Bold">CLINICAL STUDIES (14)</span>].</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_8d50fe9b-ddf0-4d8e-a885-ef09707377eb"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of levoleucovorin in the treatment of <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteosarcoma</span> did not include subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_be54d07f-1887-4c3a-93e2-40e348a3311e"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No data are available for overdosage with levoleucovorin.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_1cec049b-dddd-459a-a4a5-4249ab01edec"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Levoleucovorin is the levo isomeric form of racemic <span class="Italics">d</span><span class="Italics">,l</span>-leucovorin, present as the calcium salt. Levoleucovorin is the pharmacologically active isomer of leucovorin [(6-S)-leucovorin].</p>
<p>Levoleucovorin injection contains levoleucovorin calcium, which is one of several active, chemically reduced derivatives of folic acid. It is useful as antidote to the inhibition of dihydrofolate reductase by methotrexate. This compound has the chemical designation calcium (6S)-N-{4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl] amino]benzoyl}-L-glutamate pentahydrate. The molecular weight is 601.6 and the structural formula is:</p>
<div class="Figure">
<a name="id563"></a><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f977c9bb-bef1-4746-9894-4c29a1fdb0d8&amp;name=5c1ae5b8-4511-4e59-909d-82e73cb06139-01.jpg">
</div>
<p>Its molecular formula is: C<span class="Sub">20</span>H<span class="Sub">21</span>CaN<span class="Sub">7</span>O<span class="Sub">7Â </span><span class="Sup"> .</span> 5 H<span class="Sub">2</span>O.</p>
<p>Levoleucovorin injection is supplied as a sterile solution of either 175 mg levoleucovorin in 17.5 mL or 250 mg levoleucovorin in 25 mL. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride. Sodium hydroxide is used for pH adjustment to pH 8.0 (6.5 to 8.5).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_175690a7-79ea-47a6-9103-978c0f51b7d6"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_26b09636-5cef-4d6f-9e6e-7257e8d80e62"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><span class="Bold"><span class="Italics">12.1.1 </span></span><span class="Bold"><span class="Italics">Levoleucovorin</span></span><span class="Bold"><span class="Italics"> effects during high-dose methotrexate therapy</span></span></p>
<p>Levoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of â€œone-carbonâ€? moieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_5b376f94-94f0-4c18-b91a-45932d5c37db"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Levoleucovorin is actively<span class="Bold">Â  </span>and passively<span class="Bold">Â  </span>transported across cell membranes. <span class="Italics">In vivo</span>, levoleucovorin is converted to 5-methyltetrahydrofolic acid (5-methyl-THF), the primary circulating form of active reduced folate.<span class="Bold">Â  </span>Levoleucovorin and 5-methyl-THF are polyglutamated intracellularly by the enzyme folylpolyglutamate synthetase.<span class="Bold">Â  </span>Folylpolyglutamates are active and participate in biochemical pathways that require reduced folate.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_9c9ff2e7-3c64-4c5a-adc7-b70cc5ddf35f"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of levoleucovorin after intravenous administration of a 15 mg dose was studied in healthy male volunteers. After rapid intravenous administration, serum total tetrahydrofolate (total-THF) concentrations reached a mean peak of 1722 ng/mL. Serum (6S)-5-methyl-5,6,7,8-tetrahydrofolate concentrations reached a mean peak of 275 ng/mL and the mean time to peak was 0.9 hours. The mean terminal half-life for total-THF and (6S)-5-methyl-5,6,7,8-tetrahydrofolate was 5.1 and 6.8 hours, respectively.</p>
<p>A pharmacokinetic study was conducted in 40 healthy subjects who received a single intravenous dose of either levoleucovorin  (200 mg/m<span class="Sup">2</span>) or racemic <span class="Italics">d,l</span>-leucovorin (400 mg/m<span class="Sup">2</span>), each administered as a 2-hour infusion in a crossover design. Results indicate that the 90% confidence interval for the geometric mean ratios for both AUC<span class="Sub">0-inf</span> and C<span class="Sub">max</span> were within the standard limit of 80 to 125% for both <span class="Italics">l</span>-leucovorin and <span class="Italics">l</span>-5-methyl-THF. Therefore, the exposure to <span class="Italics">l</span>-leucovorin and 5-methyl-THF (AUC<span class="Sub">0-inf</span> and C<span class="Sub">max</span>) was comparable whether it was administered as levoleucovorin  or as <span class="Italics">d,l</span>-leucovorin. The geometric mean AUC<span class="Sub">0-inf</span> values for levoleucovorin were 30719 ng.h/mL and 31296 ng.h/mL for levoleucovorin  and <span class="Italics">d,l</span>-leucovorin, respectively. The geometric mean C<span class="Sub">max</span> values for levoleucovorin were 10895 ng/mL and 11301 ng/ mL for levoleucovorin and <span class="Italics">d</span><span class="Italics">,l</span>-leucovorin, respectively. The geometric mean AUC<span class="Sub">0-inf</span> values for 5-methyl-THF were 52105 ng.h/mL and 50137 ng.h/mL for levoleucovorin and <span class="Italics">d</span><span class="Italics">,l</span>-leucovorin, respectively. The geometric mean C<span class="Sub">max</span> values for 5-methyl-THF were 4930 ng/mL and 4658 ng/mL for levoleucovorin and <span class="Italics">d</span><span class="Italics">,l</span>-leucovorin, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_0b0c4b1d-b96a-4e9b-bc44-711977529182"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_d4c17544-8448-4eeb-a9f9-6772e11f2637"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No studies have been conducted to evaluate the potential of levoleucovorin for carcinogenesis, mutagenesis and impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_487f27bc-bb2c-427d-82c4-bfe76b5b7fc4"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">The acute intravenous LD<span class="Sub">50</span> values in adult mice and rats were 575 mg/kg (1725 mg/m<span class="Sup">2</span>) and 378 mg/kg (2268 mg/m<span class="Sup">2</span>), respectively. Signs of sedation, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, reduced motor activity, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">prostration</span>, labored breathing, and/or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span> were observed in these studies. Anticipated human dose for each administration is approximately 5 mg/m<span class="Sup">2</span> for high-dose methotrexate therapy which represents a 3-log safety margin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_11dfb07e-6f74-4534-a139-755f13b153c7"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b3aa26b7-f95b-42be-83dd-37e281d0c8eb"></a><a name="section-13.1"></a><p></p>
<h2>14.1 High Dose Methotrexate Therapy</h2>
<p class="First">The safety and efficacy of levoleucovorin rescue following high-dose methotrexate were evaluated in 16 patients age 6 to 21 who received 58 courses of therapy for <span class="product-label-link" type="condition" conceptid="4070783" conceptname="Osteosarcoma">osteogenic sarcoma</span>. High-dose methotrexate was one component of several different combination chemotherapy regimens evaluated across several trials. Methotrexate 12 g/m<span class="Sup">2</span> IV over 4 hours was administered to 13 patients, who received levoleucovorin 7.5 mg every 6 hours for 60 hours or longer beginning 24 hours after completion of methotrexate. Three patients received methotrexate 12.5 g/m<span class="Sup">2</span> IV over 6 hours, followed by levoleucovorin 7.5 mg every 3 hours for 18 doses beginning 12 hours after completion of methotrexate. The mean number of levoleucovorin doses per course was 18.2 and the mean total dose per course was 350 mg. The efficacy of levoleucovorin rescue following high-dose methotrexate was based on the adverse reaction profile. [See <span class="Bold">ADVERSE REACTIONS (6</span>)]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb207227-6a75-4cef-8190-d92582b31645"></a><a name="section-13.2"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a28bab57-c475-42da-917d-1fd7a50f7b46"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Levoleucovorin injection, 175 mg contains 17.5 mL sterile solution in a single-use vial. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.</p>
<p> 175 mg/17.5 mL solution â€“ NDC 0781-3201-94</p>
<p>Levoleucovorin injection, 250 mg contains 25 mL sterile solution in a single-use vial. Each mL contains levoleucovorin calcium pentahydrate equivalent to 10 mg levoleucovorin and 8.3 mg sodium chloride.</p>
<p> 250 mg/25 mL solution â€“ NDC 0781-3203-94</p>
<p>Store in refrigerator at 2Â°C to 8Â°C (36Â°F to 46Â°F). Protect from light. Store in carton until contents are used.</p>
<p>Manufactured in Germany by Haupt Pharma Wolfratshausen GmbH</p>
<p>Pfaffenrieder Str.5, 82515 Wolftrashausen</p>
<p>for Sandoz Inc., Princeton , NJ 08540</p>
<p>Product of Switzerland</p>
<p>Rev:. March 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_2b780186-e0cd-453b-9bde-9b7a4830306d"></a><a name="section-15"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First"><span class="Bold">NDC </span>0781-3201-94</p>
<p>Sterile Single Use Vial</p>
<p><span class="Bold">Levoleucovorin</span><span class="Bold"> Injection</span></p>
<p><span class="Bold">175 mg/17.5 mL</span></p>
<p><span class="Bold">(10 mg/mL)</span></p>
<p><span class="Italics">Present as </span><span class="Italics">levoleucovorin</span><span class="Italics"> calcium</span></p>
<p><span class="Bold">Rx only</span></p>
<p>Levoleucovorin should be dosed at half that of racemic leucovorin</p>
<p>pH 6.5 to 8.5</p>
<p>For Intravenous Use</p>
<div class="Figure">
<a name="id-1265755225"></a><img alt="175 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f977c9bb-bef1-4746-9894-4c29a1fdb0d8&amp;name=5c1ae5b8-4511-4e59-909d-82e73cb06139-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOLEUCOVORINÂ 		
					</strong><br><span class="contentTableReg">levoleucovorin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0781-3201</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOLEUCOVORIN CALCIUM PENTAHYDRATE</strong> (LEVOLEUCOVORIN) </td>
<td class="formItem">LEVOLEUCOVORIN</td>
<td class="formItem">175Â mg Â inÂ 17.5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-3201-94</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">175 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203563</td>
<td class="formItem">04/13/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Sandoz Inc
							(110342024)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5c1ae5b8-4511-4e59-909d-82e73cb06139</div>
<div>Set id: f977c9bb-bef1-4746-9894-4c29a1fdb0d8</div>
<div>Version: 3</div>
<div>Effective Time: 20150310</div>
</div>
</div>Â <div class="DistributorName">Sandoz Inc</div></p>
</body></html>
